degarelix
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms
Conditions
Prostatic Neoplasms
Trial Timeline
Oct 12, 2010 → Apr 24, 2012
NCT ID
NCT01261572About degarelix
degarelix is a phase 2 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01261572. Target conditions include Prostatic Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01261572 | Phase 2 | Completed |
Competing Products
20 competing products in Prostatic Neoplasms